The Institute of Physical Organic Chemistry offers consumers the non-narcotic analgesic Medicinal product "Nepofam-Nika" with central action under a manufacturing agreement and/or a licensing agreement, and is looking for partners to conclude a distribution services agreement.

Non-narcotic centrally acting analgesics are used to relieve pain without the risk of addiction typical of opioids. These medications act on the central nervous system, blocking pain signal transmission. They are used to treat moderate to severe pain, as well as some cases of chronic pain.

Major global manufacturers of non-narcotic centrally acting analgesics:

1. Johnson & Johnson (USA)
- Features: Manufacturer of drugs such as paracetamol (acetaminophen) and its combinations with other substances.
2. Sanofi (France)
- Features: The company produces a wide range of analgesics, including centrally acting drugs.
3. Pfizer (USA)
- Features: Manufacturer of non-narcotic analgesics such as tramadol (in combination with paracetamol).
4. Novartis (Switzerland)
- Features: The company develops and produces analgesics for the treatment of pain of various origins.
5. Bayer AG (Germany)
- Features: Manufacturer of aspirin and other non-narcotic analgesics.
6. Teva Pharmaceutical Industries (Israel)
- Features: One of the largest manufacturers of generic drugs, including non-narcotic centrally acting analgesics.

Nefopam-Nika, developed at the Institute of Physical Organic Chemistry and available as a 20 mg/ml injection solution in prefilled syringes, is a non-narcotic centrally acting analgesic.
Indications: pain of various types, intensities, and durations (postoperative pain, postpartum pain of bone or joint origin, toothache).
This drug is a non-opioid centrally acting analgesic intended for the relief of pain of various types, intensities, and durations.

The information is published in the Catalogue "100 Best Developments of the National Academy of Sciences of Belarus for the Country's Economy for 2022–2023", pp. 126–127.

Unlike centrally acting opioid analgesics, the drug is non-addictive. The developed prefilled syringe formulation allows for its use not only in medical facilities but also in emergency medical settings.

Readiness for production:
The medicinal product is registered in the Republic of Belarus. Registration Certificate No. 23/06/3300. Registration date: June 23, 2023.

The Institute of Physical Organic Chemistry is a global leader in the development, production, and use of ion-exchange fibrous materials and artificial substrates for plant cultivation. The Institute's work in membranes and membrane technologies is widely recognized. It has developed and manufactured membrane materials for ultra- and microfiltration in the form of continuous webs and capillaries, cassette, roll, and hollow fiber elements for use in the energy, food, pharmaceutical, electronics, and other industries.

The Institute's scientists have discovered and studied the following reactions: heterocyclization of azomethines with carbonyl compounds, hydroamination of oxygen-containing compounds, initiated decarboxylation of mercury acylates, and the construction of an isothiazole ring from 2-nitropentachlorobutadiene and sulfur. Convenient methods for synthesizing benzoquinolines, amines, pyridines, and organomercury compounds have been developed, as well as electrochemical methods for producing p-complexes of transition metals, and methods for synthesizing a variety of functionally substituted organohalogen compounds, carboranes, and peroxides.

Catalysts developed at the Institute have been implemented at major chemical plants. An antiblock composition preventing cellophane film from sticking together during production has been implemented industry-wide. An industrial radiation-chemical technology for producing the blood plasma substitutes "Rondex" and "Neorondex" has been developed.

The Institute's activities are aimed at developing scientific principles and technologies for creating new polymeric materials with special properties (selectively permeable, sorption, ion-exchange, and catalytically active) for use in industry, ecology, agriculture, and water treatment. The development of synthesis methods and technologies for producing medicinal substances based on amino acids and their derivatives, biologically active substances and compositions for medicine and agriculture, and functionally substituted organic and organoelement compounds.

The Institute conducts international scientific and technical cooperation through direct agreements with scientific institutions in Russia, Ukraine, Germany, Poland, Sweden, China, and elsewhere. Much attention is paid to fulfilling contracts for research and development and the manufacture of high-tech commercial products based on its own developments with organizations and firms in Saudi Arabia, Germany, Korea, Russia, and the United States.

Official website of the Institute of Physical and Organic Chemistry of the National Academy of Sciences of Belarus.

Consumers interested in purchasing the non-narcotic centrally acting analgesic drug "Nepofam-Nika" under a manufacturing agreement and/or licensing agreement.

Partners interested in purchasing the non-narcotic centrally acting analgesic drug "Nepofam-Nika" under a distribution services agreement.